The New Anticonvulsant Retigabine Favors Voltage-Dependent Opening of the Kv7.2 (KCNQ2) Channel by Binding to Its Activation Gate

Retigabine (RTG) is an anticonvulsant drug with a novel mechanism of action. It activates neuronal KCNQ-type K+ channels by inducing a large hyperpolarizing shift of steady-state activation. To identify the structural determinants of KCNQ channel activation by RTG, we constructed a set of chimeras using the neuronal Kv7.2 (KCNQ2) channel, which is activated by RTG, and the cardiac Kv7.1 (KCNQ1) channel, which is not affected by this drug. Substitution of either the S5 or the S6 segment in Kv7.2 by the respective parts of Kv7.1 led to a complete loss of activation by RTG. Trp236 in the cytoplasmic part of S5 and the conserved Gly301 in S6 (Kv7.2), considered as the gating hinge (Ala336 in Kv7.1), were found to be crucial for the RTG effect: mutation of these residues could either knockout the effect in Kv7.2 or restore it partially in Kv7.1/Kv7.2 chimeras. We propose that RTG binds to a hydrophobic pocket formed upon channel opening between the cytoplasmic parts of S5 and S6 involving Trp236 and the channel's gate, which could well explain the strong shift in voltage-dependent activation.

[1]  J. Tate,et al.  Potassium channels: structures, models, simulations. , 2002, Biochimica et biophysica acta.

[2]  Youxing Jiang,et al.  The open pore conformation of potassium channels , 2002, Nature.

[3]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[4]  W. Hauser,et al.  Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. , 1996, Mayo Clinic proceedings.

[5]  Henry A. Lester,et al.  International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. , 2003, Pharmacological reviews.

[6]  T. Friedrich,et al.  Molecular Determinants of KCNQ (Kv7) K+ Channel Sensitivity to the Anticonvulsant Retigabine , 2005, The Journal of Neuroscience.

[7]  W. Löscher,et al.  New visions in the pharmacology of anticonvulsion. , 1998, European journal of pharmacology.

[8]  D. A. Brown,et al.  Activation of Expressed KCNQ Potassium Currents and Native Neuronal M-Type Potassium Currents by the Anti-Convulsant Drug Retigabine , 2001, The Journal of Neuroscience.

[9]  R. Netzer,et al.  The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits , 2000, Neuroscience Letters.

[10]  T. Jegla,et al.  Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. , 2000, Molecular pharmacology.

[11]  U. Heinemann,et al.  Effects of Retigabine (D‐23129) on Different Patterns of Epileptiform Activity Induced by Low Magnesium in Rat Entorhinal Cortex Hippocampal Slices , 2000, Epilepsia.

[12]  C. Rundfeldt,et al.  D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. , 1996, European journal of pharmacology.

[13]  P. Christophersen,et al.  Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. , 2002, European journal of pharmacology.

[14]  A Karlin,et al.  Acetylcholine receptor channel structure in the resting, open, and desensitized states probed with the substituted-cysteine-accessibility method. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Rundfeldt,et al.  The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca++ and low Mg++ model in the hippocampal slice preparation , 1999, Epilepsy Research.

[16]  U. Heinemann,et al.  Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[17]  R. Köhling,et al.  Effects of retigabine on rhythmic synchronous activity of human neocortical slices , 2001, Epilepsy Research.

[18]  R. Horn,et al.  Stirring up controversy with a voltage sensor paddle , 2004, Trends in Neurosciences.

[19]  T. Tomson,et al.  Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII) , 2004, Epilepsy Research.

[20]  F. Bretschneider,et al.  A reduced K+ current due to a novel mutation in KCNQ2 causes neonatal convulsions , 1999, Annals of neurology.

[21]  D. Hackos,et al.  Scanning the Intracellular S6 Activation Gate in the Shaker K+ Channel , 2002, The Journal of general physiology.

[22]  J. Tamargo,et al.  Pharmacology of Cardiac Potassium Channels , 2003 .

[23]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[24]  D. A. Brown,et al.  Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone , 1980, Nature.

[25]  W. Löscher,et al.  D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures , 1996, Epilepsy Research.

[26]  T. Jentsch.  Neuronal KCNQ potassium channels:physislogy and role in disease , 2000, Nature Reviews Neuroscience.

[27]  G. Seebohm,et al.  Identification of Specific Pore Residues Mediating KCNQ1 Inactivation , 2001, The Journal of Biological Chemistry.

[28]  B S Brown,et al.  KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. , 1998, Science.

[29]  H. Lerche,et al.  Ion channel defects in idiopathic epilepsies. , 2005, Current pharmaceutical design.

[30]  W. Catterall,et al.  A Gating Hinge in Na+ Channels A Molecular Switch for Electrical Signaling , 2004, Neuron.

[31]  S. Burbidge,et al.  Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. , 2000, Molecular pharmacology.

[32]  B. Chait,et al.  The structure of the potassium channel: molecular basis of K+ conduction and selectivity. , 1998, Science.